Pulmatrix, Inc.
(NASDAQ : PULM)

( )
PULM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 0.04%283.500.0%$3952.93m
BNTXBioNTech SE 1.56%296.500.0%$1281.14m
NVAXNovavax, Inc. -1.02%179.8978.2%$855.72m
AMGNAmgen, Inc. 0.20%213.961.4%$652.89m
LGVNLongeveron Inc. 3.20%22.600.0%$531.78m
GILDGilead Sciences, Inc. 0.39%69.981.0%$517.12m
VRTXVertex Pharmaceuticals, Inc. 0.28%207.191.9%$455.37m
REGNRegeneron Pharmaceuticals, Inc. -1.05%647.162.7%$414.97m
ILMNIllumina, Inc. -0.05%375.803.3%$351.60m
SNSSSunesis Pharmaceuticals, Inc. 0.00%4.360.7%$304.78m
BIIBBiogen, Inc. -0.74%232.981.8%$295.76m
SGENSeagen Inc. 0.00%149.555.8%$157.99m
EXASEXACT Sciences Corp. 0.00%86.2618.0%$150.95m
INCYIncyte Corp. 0.00%67.332.4%$147.13m
TXG10X Genomics, Inc. 1.89%154.990.0%$140.09m

Company Profile

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.